welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

CURE DUCHENNE VENTURES ANNOUNCES FUNDING OF MESENTECH, INC. WITHIN A FUNDING COLLABORATION WITH THE CHARLES H. HOOD FOUNDATION


CURE DUCHENNE VENTURES INVESTMENT SUPPORTS THE DEVELOPMENT OF A NEW THERAPY FOR BONE WASTAGE IN DUCHENNE MUSCULAR DYSTROPHY 

Newport Beach, CA (November 10, 2020) – CureDuchenne Ventures, the research funding arm of CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy (DMD), announced an investment in Mesentech Inc., a regenerative medicine company with a prodrug platform that selectively delivers therapeutics to bone.  The investment is part of a new joint funding collaboration with the Charles H. Hood Foundation (CHF) that looks to advance early-stage research for pediatric conditions. 

CURE DUCHENNE VENTURES ANNOUNCES FUNDING OF MESENTECH, INC. WITHIN A FUNDING COLLABORATION WITH THE CHARLES H. HOOD FOUNDATION